Volume 12, Issue 4 (Winter 2009)                   2009, 12(4): 19-26 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Khayat Nouri M. Effect of dihydropyridine Ca2+ channel blockers on PTZ-induced clonic seizure threshold in mice. Journal of Inflammatory Diseases. 2009; 12 (4) :19-26
URL: http://journal.qums.ac.ir/article-1-765-en.html
, Email: khayat_nouri@yahoo.com
Abstract:   (10255 Views)
Background: Several studies have shown that the dihydropyridine calcium channel blockers such as nimodipine, nifedipine, and amlodipine have anticonvulsant effect in a range of animal models. Objective: The aim of this study was to investigate the effects of nimodipine, nifedipine and amlodipine on PTZ-induced seizure threshold with further comparison of results in mice. Methods: In 2007, this experimental study was carried out in School of Veterinary Medicine of Tabriz Islamic Azad University. Male NMRI mice were randomly divided into groups of ten members. Mice were intraperitoneally pretreated with vehicle or dihydropyridines (0.5-20 mg/kg) before the determination of intravenously PTZ-induced seizure threshold. Findings: The PTZ seizure threshold was 33.4±0.42 mg/kg in control group. In animals pretreated with nimodipine, nifedipine and amlodipine, the PTZ seizure threshold dose-dependently increased, compared with vehicle group. Nimodipine and nifedipine were found to have the highest and lowest anticonvulsant effects, respectively. Conclusion: Our results suggest that the dihydropyridine Ca2+ channel blockers induce an anticonvulsant activity probably via an antagonistic effect on voltage-gated Ca2+ channels.
Full-Text [PDF 193 kb]   (3468 Downloads)    
Type of Study: Research | Subject: Pharmacology

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2023 CC BY-NC 4.0 | Journal of Inflammatory Diseases

Designed & Developed by : Yektaweb